FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Tempus Partners with JW Pharmaceutical to Leverage Real-World Data and Biological Modeling for Enhanced R&D

Devyser Secures NMPA Approval for Devyser Compact, Expanding Genetic Testing Market in China

Qure.ai Partners with Roche’s Startup Creasphere to Enhance Healthcare Innovation in APAC

Six NHS Trusts to Deploy deepc’s AI Radiology Platform in Partnership with AI4VBC

Precision Medicine Program Marks Major Advancement in Kidney Transplant Care for Hereditary Kidney Disease Patients

Helio Genomics and Halub Medical Announce Partnership to Launch HelioLiver Dx in GCC and Middle East

Merck's KEYTRUDA® (pembrolizumab) Secures 30th European Commission Approval with Two New Indications for Gynecologic Cancers

Dyno Therapeutics Expands Collaboration with Roche to Develop Next-Generation Gene Therapies for Neurological Diseases

Philips and Medtronic Partner to Advance Stroke Care and Awareness

Qatar Precision Health Institute Unveils Genomic Data and Announces New Research Initiatives

Caris Life Sciences Partners with ECOG-ACRIN to Advance Precision Medicine in Breast Cancer Research

Celemics and Strand Life Sciences Strengthen Partnership for Enhanced NGS Analysis

Home
/
update
/
details

Nucleome Therapeutics Enters Research Collaboration with Johnson & Johnson to Advance Precision Medicines for Autoimmune Diseases

NextEdge Admin

23 Oct 2024

1 min 47 sec

Johnson & Johnson,3D genomics,partnership

Nucleome Therapeutics (“Nucleome” or “the Company”), a biotechnology firm leveraging 3D genomics to develop precision medicines for complex diseases, announced today a new research partnership with Johnson & Johnson*.

As part of the collaboration, Nucleome will apply its proprietary machine learning and high-resolution 3D genomics technologies to pinpoint specific DNA variations that increase susceptibility to autoimmune diseases. The research will also focus on uncovering the underlying pathological mechanisms driving these conditions.

By combining Nucleome’s advanced genomic platform with Johnson & Johnson’s expertise in immunology and data science, the partnership aims to identify new therapeutic target genes and the key cell types involved in autoimmune diseases. This insight could enable more precise patient classification, helping to identify those most likely to benefit from targeted treatments.

Dr. Stephen Harrison, Chief Scientific Officer of Nucleome, commented: “We are excited to collaborate with J&J to uncover new therapeutic targets and improve patient stratification strategies in autoimmune disease. Our unique technology allows us to explore how genetic variations impact gene function and contribute to disease by pinpointing the critical genes and cell types involved.”